The EDGE

Do hematopoietic stem cells get old?

J J Jung, S C Buisman and G de Haan

Leukemia 2017 31: 529-531; advance online publication, October 24, 2016; 10.1038/leu.2016.301

Commentary

Responses to pomalidomide and placebo in myelofibrosis-related anaemia

D M Ross

Leukemia 2017 31: 532-533; advance online publication, December 9, 2016; 10.1038/leu.2016.348

Reviews

Preleukemia: one name, many meanings OPEN

H P Koeffler and G Leong

Leukemia 2017 31: 534-542; advance online publication, November 30, 2016; 10.1038/leu.2016.364

Novel targets in the treatment of chronic graft-versus-host disease

A Im, F T Hakim and S Z Pavletic

Leukemia 2017 31: 543-554; advance online publication, November 30, 2016; 10.1038/leu.2016.367

Original Articles

ACUTE MYELOID LEUKEMIA

Copy-number analysis identified new prognostic marker in acute myeloid leukemia

O Nibourel, S Guihard, C Roumier, N Pottier, C Terre, A Paquet, P Peyrouze, S Geffroy, S Quentin, A Alberdi, R B Abdelali, A Renneville, C Demay, K Celli-Lebras, P Barbry, B Quesnel, S Castaigne, H Dombret, J Soulier, C Preudhomme and M H Cheok

Leukemia 2017 31: 555-564; advance online publication, September 30, 2016; 10.1038/leu.2016.265

NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis

S Struski, S Lagarde, P Bories, C Puiseux, N Prade, W Cuccuini, M-P Pages, A Bidet, C Gervais, M Lafage-Pochitaloff, C Roche-Lestienne, C Barin, D Penther, N Nadal, I Radford-Weiss, M-A Collonge-Rame, B Gaillard, F Mugneret, C Lefebvre, E Bart-Delabesse, A Petit, G Leverger, C Broccardo, I Luquet, M Pasquet and E Delabesse

Leukemia 2017 31: 565-572; advance online publication, October 3, 2016; 10.1038/leu.2016.267

ACUTE LYMPHOBLASTIC LEUKEMIA

A genome-wide association study identifies risk loci for childhood acute lymphoblastic leukemia at 10q26.13 and 12q23.1 OPEN

J Vijayakrishnan, R Kumar, M Y R Henrion, A V Moorman, P S Rachakonda, I Hosen, M I da Silva Filho, A Holroyd, S E Dobbins, R Koehler, H Thomsen, J A Irving, J M Allan, T Lightfoot, E Roman, S E Kinsey, E Sheridan, P D Thompson, P Hoffmann, M M Nöthen, S Heilmann-Heimbach, K H Jöckel, M Greaves, C J Harrison, C R Bartram, M Schrappe, M Stanulla, K Hemminki and R S Houlston

Leukemia 2017 31: 573-579; advance online publication, October 3, 2016; 10.1038/leu.2016.271

Long-term outcome of 6-month maintenance chemotherapy for acute lymphoblastic leukemia in children

M Kato, S Ishimaru, M Seki, K Yoshida, Y Shiraishi, K Chiba, N Kakiuchi, Y Sato, H Ueno, H Tanaka, T Inukai, D Tomizawa, D Hasegawa, T Osumi, Y Arakawa, T Aoki, M Okuya, K Kaizu, K Kato, Y Taneyama, H Goto, T Taki, M Takagi, M Sanada, K Koh, J Takita, S Miyano, S Ogawa, A Ohara, M Tsuchida and A Manabe

Leukemia 2017 31: 580-584; advance online publication, October 4, 2016; 10.1038/leu.2016.274

CHRONIC MYELOGENOUS LEUKEMIA

Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy

Z Chen, C Shao, W Wang, Z Zuo, X Mou, S J Hu, J A DiGiuseppe, Y Zu, L J Medeiros and S Hu

Leukemia 2017 31: 585-592; advance online publication, August 18, 2016; 10.1038/leu.2016.231

Treatment and outcome of 2904 CML patients from the EUTOS population-based registry

V S Hoffmann, M Baccarani, J Hasford, F Castagnetti, F Di Raimondo, L F Casado, A Turkina, D Zackova, G Ossenkoppele, A Zaritskey, M Höglund, B Simonsson, K Indrak, Z Sninska, T Sacha, R Clark, A Bogdanovic, A Hellmann, L Griskevicius, G Schubert-Fritschle, D Sertic, J Guilhot, S Lejniece, I Zupan, S Burgstaller, P Koskenvesa, H Everaus, P Costeas, D Lindoerfer, G Rosti, S Saussele, A Hochhaus and R Hehlmann

Leukemia 2017 31: 593-601; advance online publication, August 29, 2016; 10.1038/leu.2016.246

LYMPHOMA

Inactivation of the putative ubiquitin-E3 ligase PDLIM2 in classical Hodgkin and anaplastic large cell lymphoma OPEN

K D Wurster, F Hummel, J Richter, M Giefing, S Hartmann, M-L Hansmann, S Kreher, K Köchert, D Krappmann, W Klapper, M Hummel, S-S Wenzel, G Lenz, M Janz, B Dörken, R Siebert and S Mathas

Leukemia 2017 31: 602-613; advance online publication, August 19, 2016; 10.1038/leu.2016.238

A role for MALT1 activity in Kaposi’s sarcoma-associated herpes virus latency and growth of primary effusion lymphoma OPEN

L Bonsignore, K Passelli, C Pelzer, M Perroud, A Konrad, M Thurau, M Stürzl, L Dai, J Trillo-Tinoco, L Del Valle, Z Qin and M Thome

Leukemia 2017 31: 614-624; advance online publication, August 19, 2016; 10.1038/leu.2016.239

Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma

Y Xia, Z Y Xu-Monette, A Tzankov, X Li, G C Manyam, V Murty, G Bhagat, S Zhang, L Pasqualucci, C Visco, K Dybkaer, A Chiu, A Orazi, Y Zu, K L Richards, E D Hsi, W W L Choi, J H van Krieken, J Huh, M Ponzoni, A J M Ferreri, M B Møller, B M Parsons, J N Winter, M A Piris, J Westin, N Fowler, R N Miranda, C Y Ok, Y Li, J Li, L J Medeiros and K H Young

Leukemia 2017 31: 625-636; advance online publication, September 30, 2016; 10.1038/leu.2016.243

MULTIPLE MYELOMA, GAMMOPATHIES

Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma

J R Sawyer, E Tian, J D Shaughnessy Jr, J Epstein, C M Swanson, C Stangeby, C L Hale, L Parr, M Lynn, G Sammartino, J L Lukacs, C Stein, C Bailey, M Zangari, F E Davies, F Van Rhee, B Barlogie and G J Morgan

Leukemia 2017 31: 637-644; advance online publication, October 3, 2016; 10.1038/leu.2016.253

Pharmacogenomics and chemical library screens reveal a novel SCF^SKP2 inhibitor that overcomes Bortezomib resistance in multiple myeloma OPEN

E Malek, M A Y Abdel-Malek, S Jagannathan, N Vad, R Karns, A G Jegga, A Broyl, M van Duin, P Sonneveld, F Cottini, K C Anderson and J J Driscoll

Leukemia 2017 31: 645-653; advance online publication, September 28, 2016; 10.1038/leu.2016.258

STEM CELL TRANSPLANTATION

The proteome pattern cGvHD_MS14 allows early and accurate prediction of chronic GvHD after allogeneic stem cell transplantation

E M Weissinger, C Human, J Metzger, L Hambach, D Wolf, H T Greinix, A M Dickinson, W Mullen, D Jonigk, Z Kuzmina, H Kreipe, P Schweier, O Böhm, I Türüchanow, D Ihlenburg-Schwarz, J Raad, A Durban, M Schiemann, C Könecke, H Diedrich, E Holler, G Beutel, J Krauter, A Ganser and M Stadler

Leukemia 2017 31: 654-662; advance online publication, September 28, 2016; 10.1038/leu.2016.259

Impact of graft-versus-host disease on outcomes after unrelated cord blood transplantation

J Kanda, Y Morishima, S Terakura, A Wake, N Uchida, S Takahashi, Y Ono, Y Onishi, H Kanamori, N Aotsuka, Y Ozawa, H Ogawa, T Sakura, K Ohashi, T Ichinohe, K Kato, Y Atsuta, T Teshima and M Murata on behalf of the GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation

Leukemia 2017 31: 663-668; advance online publication, November 17, 2016; 10.1038/leu.2016.288

MOLECULAR TARGETS FOR THERAPY

Phosphorylation of a constrained azacyclic FTY720 analog enhances anti-leukemic activity without inducing S1P receptor activation

A N McCracken, R J McMonigle, J Tessier, R Fransson, M S Perryman, B Chen, A Keebaugh, E Selwan, S A Barr, S M Kim, S G Roy, G Liu, D Fallegger, L Sernissi, C Brandt, N Moitessier, A J Snider, S Clare, M Müschen, A Huwiler, M T Kleinman, S Hanessian and A L Edinger

Leukemia 2017 31: 669-677; advance online publication, August 30, 2016; 10.1038/leu.2016.244

BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells

D T Saenz, W Fiskus, T Manshouri, K Rajapakshe, S Krieger, B Sun, C P Mill, C DiNardo, N Pemmaraju, T Kadia, S Parmar, S Sharma, C Coarfa, P Qiu, S Verstovsek and K N Bhalla

Leukemia 2017 31: 678-687; advance online publication, September 28, 2016; 10.1038/leu.2016.260

DOCK2 interacts with FLT3 and modulates the survival of FLT3-expressing leukemia cells

M Wu, M Hamaker, L Li, D Small and A S Duffield

Leukemia 2017 31: 688-696; advance online publication, October 17, 2016; 10.1038/leu.2016.284

IMMUNOTHERAPY

PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies

M H Qazilbash, E Wieder, P F Thall, X Wang, R Rios, S Lu, S Kanodia, K E Ruisaard, S A Giralt, E H Estey, J Cortes, K V Komanduri, K Clise-Dwyer, G Alatrash, Q Ma, R E Champlin and J J Molldrem

Leukemia 2017 31: 697-704; advance online publication, September 22, 2016; 10.1038/leu.2016.254

CYTOGENETICS AND MOLECULAR GENETICS

The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases

A Stengel, W Kern, T Haferlach, M Meggendorfer, A Fasan and C Haferlach

Leukemia 2017 31: 705-711; advance online publication, September 29, 2016; 10.1038/leu.2016.263

EPIDEMIOLOGY

The cohesin subunit Rad21 is a negative regulator of hematopoietic self-renewal through epigenetic repression of Hoxa7 and Hoxa9

J B Fisher, J Peterson, M Reimer, C Stelloh, K Pulakanti, Z J Gerbec, A M Abel, J M Strouse, C Strouse, M McNulty, S Malarkannan, J D Crispino, S Milanovich and S Rao

Leukemia 2017 31: 712-719; advance online publication, August 24, 2016; 10.1038/leu.2016.240

ANIMAL MODELS

Hemopoietic-specific Sf3b1-K700E knock-in mice display the splicing defect seen in human MDS but develop anemia without ring sideroblasts OPEN

A Mupo, M Seiler, V Sathiaseelan, A Pance, Y Yang, A A Agrawal, F Iorio, R Bautista, S Pacharne, K Tzelepis, N Manes, P Wright, E Papaemmanuil, D G Kent, P C Campbell, S Buonamici, N Bolli and G S Vassiliou

Leukemia 2017 31: 720-727; advance online publication, September 8, 2016; 10.1038/leu.2016.251

Letters To The Editor

Prevalence and characteristics of survivors from acute myeloid leukemia in Sweden OPEN

G Juliusson, J Abrahamsson, V Lazarevic, P Antunovic, Å Derolf, H Garelius, S Lehmann, K Myhr-Eriksson, L Möllgård, B Uggla, A Wahlin, L Wennström, M Höglund and for the Swedish AML Group and the Swedish Childhood Leukemia Group

Leukemia 2017 31: 728-731; advance online publication, October 31, 2016; 10.1038/leu.2016.312

Plastic CD34 and CD38 expression in adult B–cell precursor acute lymphoblastic leukemia explains ambiguity of leukemia-initiating stem cell populations OPEN

F Lang, B Wojcik, S Bothur, C Knecht, J H F Falkenburg, T Schroeder, H Serve, O G Ottmann and M A Rieger

Leukemia 2017 31: 731-734; advance online publication, November 2, 2016; 10.1038/leu.2016.315

Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial

J Edelmann, E Tausch, D A Landau, S Robrecht, J Bahlo, K Fischer, A M Fink, J Bloehdorn, K Holzmann, S Böttcher, L Werner, M Kneba, J G Gribben, D S Neuberg, C J Wu, M Hallek, H Döhner and S Stilgenbauer

Leukemia 2017 31: 734-738; advance online publication, November 2, 2016; 10.1038/leu.2016.317

PD-L1 (CD274) promoter methylation predicts survival in patients with acute myeloid leukemia

D Goltz, H Gevensleben, S Grünen, J Dietrich, G Kristiansen, J Landsberg and D Dietrich

Leukemia 2017 31: 738-743; advance online publication, November 14, 2016; 10.1038/leu.2016.328

Novel ALK fusion in anaplastic large cell lymphoma involving EEF1G, a subunit of the eukaryotic elongation factor-1 complex

G Palacios, T I Shaw, Y Li, R K Singh, M Valentine, J T Sandlund, M S Lim, C G Mullighan and V Leventaki

Leukemia 2017 31: 743-747; advance online publication, November 14, 2016; 10.1038/leu.2016.331

The cryptic IRF2BP2-RARA fusion transforms hematopoietic stem/progenitor cells and induces retinoid-sensitive acute promyelocytic leukemia

J V Jovanovic, M C Chillón, C Vincent-Fabert, R Dillon, E Voisset, N C Gutiérrez, R G Sanz, A A M Lopez, Y G Morgan, J Lok, E Solomon, E Duprez, M G Díaz and D Grimwade

Leukemia 2017 31: 747-751; advance online publication, November 22, 2016; 10.1038/leu.2016.338

Phosphatase PRL2 promotes oncogenic NOTCH1-Induced T-cell leukemia

M Kobayashi, Y Bai, S Chen, R Gao, C Yao, W Cai, A A Cardoso, J Croop, Z-Y Zhang and Y Liu

Leukemia 2017 31: 751-754; advance online publication, December 9, 2016; 10.1038/leu.2016.340

Bcl-2 protein family expression pattern determines synergistic pro-apoptotic effects of BH3 mimetics with hemisynthetic cardiac glycoside UNBS1450 in acute myeloid leukemia OPEN

C Cerella, A Gaigneaux, A Mazumder, J-Y Lee, E Saland, F Radogna, T Farge, F Vergez, C Récher, J-E Sarry, K-W Kim, H Y Shin, M Dicato and M Diederich

Leukemia 2017 31: 755-759; advance online publication, November 22, 2016; 10.1038/leu.2016.341

Mutational landscape in children with myelodysplastic syndromes is distinct from adults: specific somatic drivers and novel germline variants

V Pastor, S Hirabayashi, A Karow, J Wehrle, E J Kozyra, R Nienhold, G Ruzaike, D Lebrecht, A Yoshimi, M Niewisch, T Ripperger, G Göhring, I Baumann, S Schwarz, B Strahm, C Flotho, R C Skoda, C M Niemeyer and M W Wlodarski

Leukemia 2017 31: 759-762; advance online publication, November 23, 2016; 10.1038/leu.2016.342

Diagnosis and relapse: cytogenetically normal acute myelogenous leukemia without FLT3-ITD or MLL-PTD

W Chien, Q-Y Sun, L-W Ding, A Mayakonda, S Takao, L Liu, S L Lim, K T Tan, M Garg, A De Sousa Maria Varela, J Xiao, N Jacob, K Behrens, C Stocking, M Lill, V Madan, N Hattori, S Gery, S Ogawa, S Wakita, T Ikezoe, L-Y Shih, T Alpermann, T Haferlach, H Yang and H P Koeffler

Leukemia 2017 31: 762-766; advance online publication, November 24, 2016; 10.1038/leu.2016.343

Correspondence

Reply to Goel et al. ‘TP53 mutation allele-burden and disease outcome in MDS/AML’

D A Sallman, R Komrokji, A List and E Padron

Leukemia 2017 31: 767-768; advance online publication, October 14, 2016; 10.1038/leu.2016.257

Response to Harrison et al. ‘Clinically relevant differences between BCSH and WHO diagnostic criteria for ET’ OPEN

H Gisslinger, G Jeryczynski, A Wölfler, C Beham-Schmid and J Thiele

Leukemia 2017 31: 768-769; advance online publication, November 29, 2016; 10.1038/leu.2016.319

Response to ‘Overexpression of ABCB1 as prediction marker for CML: How close we are to translation into clinics?’

L N Eadie, T P Hughes and D L White

Leukemia 2017 31: 769-770; advance online publication, December 2, 2016; 10.1038/leu.2016.335

Cardiologist’s perspective to the European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

C Constance, L Trudeau, E M Jolicoeur, D Langleben, A Rivard, R Chehayeb, M-A Côté and D Delgado

Leukemia 2017 31: 771-772; advance online publication, December 2, 2016; 10.1038/leu.2016.336

Reply to Constance et al.

J L Steegmann, M Baccarani and R E Clark

Leukemia 2017 31: 772-773; advance online publication, December 6, 2016; 10.1038/leu.2016.337

Corrigenda

Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria

H Gisslinger, G Jeryczynski, B Gisslinger, A Wölfler, S Burgstaller, V Buxhofer-Ausch, M Schalling, M-T Krauth, A-I Schiefer, C Kornauth, I Simonitsch-Klupp, C Beham-Schmid, L Müllauer and J Thiele

Leukemia 2017 31: 774-775; 10.1038/leu.2016.291

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis

C N Harrison, A M Vannucchi, J-J Kiladjian, H K Al-Ali, H Gisslinger, L Knoops, F Cervantes, M M Jones, K Sun, M McQuitty, V Stalbovskaya, P Gopalakrishna and T Barbui

Leukemia 2017 31: 775; 10.1038/leu.2016.323